P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL

Background. Depth of response is a central determinant of clinical outcomes in multiple myeloma (MM), and bone-marrow-based minimal residual disease (MRD) has emerged as one of the strongest surrogate biomarkers for progression-free (PFS) and overall survival (OS). However, MRD assessment remains i...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	J.X. Jin, V.R. Ginde, S. Huhn, Ph. Reichert, U. Bertsch, R. Fenk, B. Besemer, A. Boquoi, R. Schroers, I. Von Metzler, M. Hänel, Ch. Mann, L.B. Leypoldt, B. Heilmeier, C. Scheid, T. Peters-Regehr, I.W. Blau, C. Müller-Tidow, S. Luntz, T.A.W. Holderried, K. Trautmann-Grill, D. Gezer, M. Klaiber-Hakimi, M. Müller, E. Shumilov, W. Knauf, C.S. Michel, T. Geer, H. Riesenberg, Ch. Lutz, M.S. Raab, N. Weinhold, M. Hoffmann, A. Benner, P. Findeisen, K.C. Weisel, H.J. Salwender, H. Goldschmidt, E.K. Mai
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Ferrata Storti Foundation 2026-04-01
Rangatū:	Haematologica
Urunga tuihono:	https://haematologica.org/article/view/14035
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!